View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	May 14, 2020
Cover [Abstract]
Entity Registrant Name	DELCATH SYSTEMS, INC.
Entity Central Index Key	0000872912
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Quarterly Report	true
Document Transition Report	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Entity File Number	001-16133
Entity Tax Identification Number	06-1245881
Entity Address, Address Line One	1633 Broadway
Entity Address Address Line2	Suite 22C
Entity Address City Or Town	New York
Entity Address State Or Province	NY
Entity Address Postal Zip Code	10019
City Area Code	212
Local Phone Number	489-2100
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		2,760,401
Document Fiscal Year Focus	2020
Trading Symbol	DCTH
Title of 12(b) Security	Common stock
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Security Exchange Name	NASDAQ

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Current assets

Cash and cash equivalents

$ 4,540

$ 10,002

Restricted cash

181

Accounts receivables, net

Inventories

790

654

Prepaid expenses and other current assets

2,642

1,759

Total current assets

8,222

12,617

Property, plant and equipment, net

867

735

Right-of-use assets

688

860

Total assets

9,777

14,212

Current liabilities

Accounts payable

4,997

4,533

Accrued expenses

7,424

6,947

Lease liabilities, current portion

622

664

Warrant liability

3,368

Total current liabilities

13,043

15,512

Deferred revenue

2,672

2,860

Lease liabilities, long-term portion

197

Convertible notes payable, long-term

2,000

Total liabilities

17,782

20,569

Commitments and contingencies

Stockholders' deficit

Preferred stock, $.01 par value; 10,000,000 shares authorized; 41,447 and 41,517 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

Common stock, $.01 par value; 1,000,000,000 shares authorized; 72,773 and 67,091 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively*

^[1]

Additional paid-in capital

370,933

364,785

Accumulated deficit

(379,032)

(371,171)

Accumulated other comprehensive income

Total stockholders' deficit

(8,005)

(6,357)

Total liabilities and stockholders' deficit

$ 9,777

$ 14,212

[1]	* reflects, a one-for-seven hundred (1:700) reverse stock split effected on December 24, 2019.

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	41,447	41,517
Preferred stock, shares outstanding (in shares)	41,447	41,517
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	72,773	67,091
Common stock, shares outstanding (in shares)	72,773	67,091

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Cost of goods sold

$ (78)

$ (96)

Gross profit

216

174

Operating expenses:

Research and development expenses

2,974

3,298

Selling, general and administrative expenses

2,316

2,549

Total operating expenses

5,290

5,847

Operating loss

(5,074)

(5,673)

Change in fair value of the warrant liability, net

(2,832)

Interest expense

(56)

(2,229)

Other income

101

Net loss

(7,861)

(7,893)

Other comprehensive (loss) income:

Foreign currency translation adjustments

Total other comprehensive loss

$ (7,796)

$ (7,836)

Common share data:

Basic loss per common share

^[1]

$ (108.07)

$ (75.11)

Diluted loss per common share

^[1]

$ (108.07)

$ (75.11)

Weighted average number of basic shares outstanding

^[1]

72,740

105,084

Weighted average number of diluted shares outstanding

^[1]

72,740

105,084

Product Revenue [Member]

Revenue

$ 176

$ 90

Other Revenue [Member]

Revenue

$ 118

$ 180

[1]	reflects, one-for-seven hundred (1:700) reverse stock split effected on December 24, 2019.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)	Dec. 24, 2019
Income Statement [Abstract]
Reverse stock split	1:700
Reverse stock split ratio	0.00142

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Preferred Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]
Balance at Dec. 31, 2018	$ (14,939)				$ (344,054)	$ 50
Balance (in shares) at Dec. 31, 2018		14,715	101	329,065
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	54			$ 54
Compensation expense for issuance of restricted stock	4			4
Compensation expense for issuance of restricted stock (in shares)		20
Issuance of Series D Preferred Stock	150			150
Issuance of Series D Preferred Stock (in shares)			15
Conversion of Series D Preferred Stock to Debt	(1,160)			$ (1,160)
Conversion of Series D Preferred Stock to Debt (in shares)			(116)
Exercise of pre-funded warrants (in shares)		5,885
Net loss	(7,893)				(7,893)
Total comprehensive income	7					7
Balance at Mar. 31, 2019	(23,777)				(351,947)	57
Balance (in shares) at Mar. 31, 2019		20,620		328,113
Balance at Dec. 31, 2019	(6,357)	$ 1		$ 364,785	(371,171)	28
Balance (in shares) at Dec. 31, 2019		67,091	41,517
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	25			25
Compensation expense for issuance of restricted stock	$ 30			30
Compensation expense for issuance of restricted stock (in shares)	2,717	2,717
Conversion of Preferred stock into common stock (in shares)		2,915	(70)
Fractional rounding related to reverse stock split (in shares)		50
Registration of Series E and Series E-1 Preferred stock and related warrants	$ (106)			(106)
Fair value of warrants reclassified from liability to equity	6,199			6,199
Net loss	(7,861)				(7,861)
Total comprehensive income	65					65
Balance at Mar. 31, 2020	$ (8,005)	$ 1		$ 370,933	$ (379,032)	$ 93
Balance (in shares) at Mar. 31, 2020		72,773	41,447

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) (Parenthetical)	Dec. 24, 2019
Statement Of Stockholders Equity [Abstract]
Reverse stock split	1:700
Reverse stock split ratio	0.00142

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (7,861)	$ (7,893)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	25	54
Restricted stock compensation expense	30	4
Depreciation expense	48	65
Amortization of right of use assets	172	0
Warrant liability fair value adjustment	2,832	(7)
Non-cash interest income	(3)	0
Interest expense accrued related to convertible notes	40	51
Debt discount amortization	0	2,160
Changes in assets and liabilities:
Decrease in prepaid expenses and other assets	(880)	(108)
Decrease in accounts receivable	(48)	523
Decrease in inventories	(136)	61
Decrease in accounts payable and accrued expenses	901	2,902
Deferred revenue	(188)	(120)
Principal payments on operating leases	(161)	0
Decrease in other non-current liabilities	0	(462)
Net cash used in operating activities	(5,229)	(2,770)
Cash flows from investing activities:
Purchase of property, plant and equipment	(180)	(2)
Net cash (used in) investing activities	(180)	(2)
Cash flows from financing activities:
Principal payments on financing leases	(11)	0
Net proceeds from the issuance of debt	0	400
Net cash (used in) provided by financing activities	(117)	550
Foreign currency effects on cash	64	(30)
Net (decrease) increase in cash and cash equivalents	(5,462)	(2,252)
Cash and cash equivalents:
Beginning of period	10,183	3,578
End of period	4,721	1,326
Series D Preferred Stock [Member]
Cash flows from financing activities:
Net proceeds from sale of Series D Preferred Stock	0	150
Series E and Series E-1 Preferred Stock and Related Warrants [Member]
Cash flows from financing activities:
Registration of Series E and Series E-1 Preferred stock and related warrants	$ (106)	$ 0

General

3 Months Ended

Mar. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

General

(1)

General

The unaudited interim condensed consolidated financial statements of Delcath Systems, Inc. (“Delcath” or the “Company”) as of and for the three months ended March 31, 2020 and 2019 should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the “Annual Report”), which was filed with the Securities Exchange Commission (the “SEC”) on March 25, 2020 and may also be found on the Company’s website (www.delcath.com). In these notes to the condensed consolidated financial statements the terms “us”, “we” or “our” refer to Delcath and its consolidated subsidiaries.

Description of Business

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (“Melphalan/HDS”) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, our system is commercially available under the trade name Delcath Hepatic CHEMOSAT^® Delivery System for Melphalan (“CHEMOSAT”), where it has been used at major medical centers to treat a wide range of cancers of the liver.

Our clinical development program (“CDP”) for Melphalan/HDS is comprised of The FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (the “FOCUS Trial”), a global registration clinical trial that is investigating objective response rate in mOM, and the ALIGN Trial, a global Phase 3 clinical trial for ICC (the “ALIGN Trial”). Our CDP also includes a registry for CHEMOSAT commercial cases performed in Europe and sponsorship of select investigator-initiated trials (“IITs”).

The recent outbreak of a novel strain of coronavirus (COVID-19) has had an impact on our ability to monitor data at our clinical trial sites and is likely to cause a decline in product revenue for the forseeable future as many hospitals are prioritizing the treatment of patients diagnosed with COVID-19. This situation is rapidly changing and additional impacts to the business may arise that we are not aware of currently. The ultimate impact of the pandemic on the Company’s results of operations, financial position, liquidity or capital resources cannot be reasonably estimated at this time.

Liquidity

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We anticipate incurring losses until such time, if ever, that it can generate significant sales. As discussed in Note 13, in May 2020 we consummated an underwritten public offering resulting in gross proceeds of approximately $22.0 million. We expect that the proceeds of the offering and our existing cash resources will be sufficient to fund our expected operations through the second quarter of 2021. We may need to raise additional capital in the future to support our operations. We expect that any such financing activity will involve the public or private offering of our equity and/or equity-related securities. If we are unable to obtain sufficient capital to fund our operations, we would be required to curtail certain aspects of our operations or consider other means of obtaining additional financing, although there is no guarantee that we would be able to obtain the financing necessary to continue its operations.

Basis of Presentation

These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation.

The preparation of interim condensed consolidated financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended March 31, 2020 and 2019; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.

Significant Accounting Policies

A description of our significant accounting policies has been provided in Note 3 Summary of Significant Accounting Policies to the Consolidated Financial Statements included in the Company’s Annual Report filed for the fiscal year ended December 31, 2019.

Recently Issued Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Simplifying the Accounting for Income Taxes. The list of changes is comprehensive, however the changes will not significantly impact the Company due to the full valuation allowance that is recorded against the Company’s deferred tax assets. Early adoption of ASU 2019-12 is permitted, including adoption in any interim period for public business entities for periods for which financial statements have not yet been issued. An entity that elects to early adopt the amendments in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity that elects early adoption must adopt all the amendments in the same period. The Company will adopt ASU 2019-12 in 2021.

Restricted Cash

3 Months Ended

Mar. 31, 2020

Restricted Cash [Abstract]

Restricted Cash

(2)	Restricted Cash

Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded in Restricted Cash on the balance sheets. Restricted cash does not include required minimum balances.

Cash, cash equivalents, and restricted cash balances were as follows:

	March 31,		December 31,
(in thousands)		2020		2019
Cash and cash equivalents	$	4,540	$	10,002
Letters of credit		131		131
Security for credit cards		50		50
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$	4,721	$	10,183

Inventories

3 Months Ended

Mar. 31, 2020

Inventory Disclosure [Abstract]

Inventories

(3)	Inventories

Inventories consist of the following:

	March 31,		December 31,
(in thousands)	2020		2019
Raw materials	$	448	$	375
Work-in-process		342		279
Total inventories	$	790	$	654

Prepaid Expenses and Other Current Assets

3 Months Ended

Mar. 31, 2020

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Prepaid Expenses And Other Current Assets

(4)	Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

	March 31,		December 31,
(in thousands)	2020		2019
Clinical trial expenses	$	1,497	$	725
Insurance premiums		423		589
Professional Service Fees		518		—
Other¹		204		445
Total prepaid expenses and other current assets	$	2,642	$	1,759

¹Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% of prepaid expenses and other current assets at March 31, 2020 and December 31, 2019.

Property, Plant, and Equipment

3 Months Ended

Mar. 31, 2020

Property Plant And Equipment [Abstract]

Property, Plant, and Equipment

(5)	Property, Plant, and Equipment

Property, plant, and equipment consist of the following:

	March 31,			December 31,			Estimated
(in thousands)	2020			2019			Useful Life
Buildings and land	$	634		$	589		30 years - Buildings
Enterprise hardware and software		1,763			1,739		3 years
Leaseholds		1,787			1,695		Lesser of lease term or estimated useful life
Equipment		1,032			1,025		7 years
Furniture		202			198		5 years
Property, plant and equipment, gross		5,418			5,246
Accumulated depreciation		(4,551	)		(4,511	)
Property, plant and equipment, net	$	867		$	735

Depreciation expense for the three months ended March 31, 2020 was approximately $0.1 million as compared to approximately $0.1 million for the same period in 2019.

Accrued Expenses

3 Months Ended

Mar. 31, 2020

Payables And Accruals [Abstract]

Accrued Expenses

(6)	Accrued Expenses

Accrued expenses consist of the following:

	March 31,		December 31,
(in thousands)	2020		2019
Clinical Expenses	$	2,580	$	2,497
Compensation, excluding taxes		3,933		3,525
Professional fees		361		263
Other¹		550		662
Total accrued expenses	$	7,424	$	6,947

¹Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at March 31, 2020 and December 31, 2019.

Leases

3 Months Ended

Mar. 31, 2020

Leases [Abstract]

Leases

(7)

Leases

The Company recognizes right-of-use (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company leases its facilities under non-cancellable operating and financing leases.

The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the ROU asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.

The following table summarizes the Company’s operating and financing leases as of and for the three months ended March 31, 2020:

(in thousands)	US			Ireland			Total
Lease Cost
Operating lease cost	$	118		$	52		$	170
Financing lease cost	12				—			12
Sublease income		—			(43	)		(43	)
Total	$	130		$	9		$	139

Other information
Operating cash flows out from operating leases		(118	)		(52	)		(170	)
Operating cash flows in from operating leases		-			43			43
Operating cash flows out from financing leases		(11	)		—			(11	)
Right-of-use assets exchanged for new operating lease liabilities		—			—			—
Weighted average remaining lease term		0.9			1.3
Weighted average discount rate - operating leases		8	%		8	%

Maturities of the Company’s operating leases, excluding short-term leases, are as follows:

(in thousands)	US			Ireland			Total
Year ended December 31, 2020	$	369		$	154		$	523
Year ended December 31, 2021		78			120			198
Total		447			274			721
Less present value discount		(17	)		(15	)		(32	)
Operating lease liabilities included in the condensed consolidated balance sheet at March 31, 2020	$	430		$	259		$	689

Outstanding Debt

3 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

Outstanding Debt

(8)	Outstanding Debt

On June 6, 2019, the Company entered into an agreement with two institutional investors, pursuant to which the investors agreed to transfer and surrender to the Company for cancellation of warrants to purchase 5,605 shares of the Company’s common stock (the “Series D Warrants”) and warrants to purchase 0.1 million shares of the Company’s common stock (the “Pre-Funded Series D Warrants”). Under the terms of the Purchase Agreement, the Company agreed to sell and issue to the investors 8% Senior Secured Promissory Notes in an aggregate principal amount of $2.0 million in full payment and satisfaction of the purchase price for the Series D Warrants and Pre-Funded Series D Warrants. This agreement was effective on July 15, 2019, upon the closing of the Company’s Private Placement discussed further in Notes 10 and 11 to the Company’s audited consolidated financial statements contained in its Annual Report for the fiscal year ended December 31, 2019. Following the closing of the Private Placement, the Company entered into an agreement under which the 8% Senior Secured Promissory Notes became convertible into shares of Series E Preferred Stock and Warrants (the “Unit”) at the price of $1,500 per Unit. The principal is recognized in Convertible notes payable, long-term on the Condensed Consolidated Balance Sheet.

The following tables provide a summary of the various notes outstanding at March 31, 2020:

Conversion

price

Current interest

rate

Principal

Long term convertible notes payable

8.0% July 2019 Notes

1,500

2,000,000

Stockholders' Equity

3 Months Ended

Mar. 31, 2020

Stockholders Equity Note [Abstract]

Stockholders' Equity

(9)	Stockholders’ Equity

Preferred Stock

Series E and Series E-1 Preferred Stock

On July 11, 2019, the Company entered into a securities purchase agreement with certain accredited investors pursuant to which Delcath sold to investors an aggregate of 20,000 shares of our Series E convertible preferred stock, par value $0.01 per share, or the Series E Preferred Stock, at a price of $1,000 per share and a warrant, or a 2019 E Warrant, to purchase a number of shares of common stock equal to the number of shares of common stock issuable upon conversion of the Series E Preferred Stock purchased by the investor, or the July 2019 Private Placement. In connection with the July 2019 Private Placement, the Company exchanged $11.8 million of debt, interest and Series D Warrants for 11,500 shares of Series E Preferred Stock and related 2019 Warrants, $0.1 million in accounts payables for 149 shares of Series E Preferred Stock and related 2019 Warrants and issued 923 shares of Series E Preferred Stock and related 2019 Warrants to certain investors in exchange for a waiver of rights under exchange agreements signed in December 2018 and March 2019, or the Debt Exchange.

On August 19, 2019, the Company entered into a securities purchase agreement with certain accredited investors pursuant to which Delcath sold to investors an aggregate of 9,510 shares of Series E-1 convertible preferred stock, par value $0.01 per share, or the Series E-1 Preferred Stock, at a price of $1,000 per share and a warrant, or a 2019 E-1 Warrant, and together with the 2019 E Warrant, the 2019 Warrants, to purchase a number of shares of common stock of the Company equal to the number of shares of common stock issuable upon conversion of the Series E-1 Preferred Stock purchased by the investor, or the August 2019 Private Placement, and, collectively with the July 2019 Private Placement, the Private Placements.

Each share of Series E Preferred Stock and Series E-1 Preferred Stock, or, collectively, the Preferred Stock, is convertible at any time at the option of the holder into the number of shares of common stock determined by dividing the current conversion price. At March 31, 2020, the conversion price was $23.04 and was subsequently adjusted to $10.00 upon the pricing of a $22.0 million offering on May 1, 2020 and discussed further in Note 13. The holders of the Preferred Stock are entitled to receive dividends on shares of Preferred Stock equal (on an “as converted” basis) to and in the same form as dividends paid on shares of the common stock. Any such dividends that are not paid to the holders of the Preferred Stock will increase the stated value. No other dividends will be paid on shares of Preferred Stock.

Each 2019 Warrant had an exercise price equal to $23.04 at March 31, 2020. The exercise price was subsequently adjusted to $10.00 upon the pricing of a $22.0 million offering on May 1, 2020 and discussed further in Note 13. The 2019 Warrants are exercisable until 5:00 p.m. (NYC time) on December 24, 2024.

As of March 31, 2020, there were 41,447 shares of Preferred Stock outstanding and 1.8 million 2019 Warrants outstanding.

Common Stock Issuances

During the three months ended March 31, 2020 the Company issued 2,915 shares of the Company’s common stock pursuant to conversions of Series E and Series E-1 Preferred Stock.

Share-Based Compensation

The Company’s 2019 Equity Incentive Plan (the “Plan”) allows for grants in the form of incentive stock options, nonqualified stock options, stock units, stock awards, stock appreciation rights, and other stock-based awards. All of the Company’s officers, directors, employees, consultants and advisors are eligible to receive grants under the Plan. The maximum number of shares reserved for issuance under the Plan is 2,142. Options to purchase shares of common stock are granted at exercise prices not less than 100% of fair value on the dates of grant. As of March 31, 2020, the Plan had approximately 502 shares available for grant.

The following is a summary of stock option activity under the Plan for the three months ended March 31, 2020:

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding at December 31, 2019		1,640	$	196.70	9.1	$	—
Granted		—
Exercised		—
Cancelled/Forfeited		—
Outstanding at March 31, 2020		1,640	$	196.70	8.9	$	—
Exercisable at March 31, 2020		1,640	$	196.70	8.9	$	—

At March 31, 2020, there was no unrecognized compensation expense related to non-vested share-based compensation awards under the plans for employee and board stock option grants. For the three months ended March 31, 2020, the Company recognized share-based compensation expense of approximately $54,000 in the statement of operations, which includes 2,717 shares of restricted common stock issued as compensation for certain advisory services. For the same period in 2019, the Company recognized share-based compensation expense of approximately $54,000 in the statement of operations.

	Three months ended March 31,
(in thousands)	2020		2019
Selling, general and administrative	$	49	$	43
Research and development		5		11
Total	$	54	$	54

Warrants

The following is a summary of warrant activity for the three months ended March 31, 2020:

	Warrants			Exercise Price per Share	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)
Outstanding at December 31, 2019		1,826,608		$7.00 - $23.04	$	23.04		5.0
Issued		—
Exercised		—
Expired		(9	)
Outstanding at March 31, 2020		1,826,599		$7.00 - $23.04	$	23.04		4.7

Fair Value Measurements

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

(10)	Fair Value Measurements

As a result of the expiration of certain provisions in the 2019 Warrants they were reclassified from liability to equity on February 19, 2020.

The table below presents the activity within Level 3 of the fair value hierarchy for the three months ended March 31, 2020:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

(in thousands)	Warrant Liability
Balance at December 31, 2019	$	3,368
Total change in the liability included in earnings		2,832
Fair value of warrants reclassified from liability to equity		(6,200	)
Balance at March 31, 2020	$	—

The fair value of the outstanding warrants at February 19, 2020, the date the 2019 Warrants were no longer classified as a liability, and December 31, 2019 was determined by using option pricing models with the following assumptions:

	February 19,	December 31,
	2020	2019
Expected life (in years)	4.3		4.6
Expected volatility	208.2%	207.5%
Risk-free interest rates	1.4%	1.7%

The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2020, aggregated by the level in the fair value hierarchy within which those measurements fall in accordance with ASC 820.

	Assets and Liabilities Measured at Fair Value on a Recurring Basis
(in thousands)	Level 1				Level 2				Level 3				Total
	March 31, 2020		December 31, 2019		March 31, 2020		December 31, 2019		March 31, 2020		December 31, 2019		March 31, 2020		December 31, 2019
Liabilities
Derivative instrument liabilities	$	—	$	—	$	—	$	—	$	—	$	3,368	$	—	$	3,368

For the periods ended March 31, 2020 and December 31, 2019, there were no transfers in or out of Level 1, 2 or 3 inputs.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Net Loss per Common Share

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Net Loss per Common Share

(11)	Net Loss per Common Share

Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period, without consideration of potentially dilutive securities except for those shares that are issuable for little or no cash consideration. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are generally deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. However, in certain periods in which the exercise price of the warrants was less than the last reported sales price of Delcath’s common stock on the final trading day of the period and there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, the impact of gains related to the mark-to-market adjustment of the warrants outstanding at the end of the period is reversed and the treasury stock method is used to determine diluted earnings per share.

The following potentially dilutive securities were excluded from the computation of earnings per share as of March 31, 2020 and 2019 because their effects would be anti-dilutive:

	March 31,
	2020		2019
Stock options		1,640		1,166,667
Common stock warrants - equity		1,826,599		4,202,909
Common stock warrants - liabilities		—		189,029
Common stock reserved for conversion of preferred shares		1,799,093		—
Assumed conversion of convertible notes		63,493		268,558
Total		3,690,825		5,827,163

Taxes

3 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Abstract]

Taxes

(12)

Taxes

As discussed in Note 14 Income Taxes of the Company’s Annual Report, the Company has a valuation allowance against the full amount of its net deferred tax assets. The Company currently provides a valuation allowance against deferred tax assets when it is more likely than not that some portion or all of its deferred tax assets will not be realized. The Company has not recognized any unrecognized tax benefits in its balance sheet.

The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. Additional information regarding the statutes of limitations can be found in Note 14 Income Taxes of the Company’s Annual Report.

On March 27, 2020, President Trump signed into law the $2 trillion bipartisan Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748). The CARES Act includes a variety of economic and tax relief measures intended to stimulate the economy, including loans for small businesses, payroll tax credits/deferrals, and corporate income tax relief. Due to the Company’s history of tax loss carryforwards and full valuation allowance, the CARES Act did not have a significant effect to the income tax provision, as the corporate income tax relief was directed towards cash taxpayers.

Subsequent Events

3 Months Ended

Mar. 31, 2020

Subsequent Events [Abstract]

Subsequent Events

(13)	Subsequent Events

Public Offering and Nasdaq Uplisting

On May 5, 2020, the Company closed a public offering of 2.2 million shares of common stock (or common stock equivalents) and Series F warrants to purchase up to 2.2 million shares of common stock. Delcath received gross proceeds of approximately $22.0 million from the offering, before deducting the underwriting discount and estimated offering expenses. The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-235904) previously filed with the SEC and declared effective on April 30, 2020. In connection with this offering, the Company’s common stock was approved for listing and began trading on the Nasdaq Capital Market on May 1, 2020. As a result of this offering, the Series E and Series E-1 Preferred Stock conversion price was adjusted to $10.00 and the exercise price of the 2019 Warrants was adjusted to $10.00.

Preferred Stock Conversions

From April 1, 2020 through May 14, 2020, the Company issued 0.8 million shares of Common Stock upon the conversion of Series E and Series E-1 Preferred Stock.

General (Policies)	3 Months Ended
General (Policies)	Mar. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Liquidity	Liquidity The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We anticipate incurring losses until such time, if ever, that it can generate significant sales. As discussed in Note 13, in May 2020 we consummated an underwritten public offering resulting in gross proceeds of approximately $22.0 million. We expect that the proceeds of the offering and our existing cash resources will be sufficient to fund our expected operations through the second quarter of 2021. We may need to raise additional capital in the future to support our operations. We expect that any such financing activity will involve the public or private offering of our equity and/or equity-related securities. If we are unable to obtain sufficient capital to fund our operations, we would be required to curtail certain aspects of our operations or consider other means of obtaining additional financing, although there is no guarantee that we would be able to obtain the financing necessary to continue its operations.
Basis of Presentation	Basis of Presentation These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation. The preparation of interim condensed consolidated financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended March 31, 2020 and 2019; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.
Recently Adopted and Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Simplifying the Accounting for Income Taxes. The list of changes is comprehensive, however the changes will not significantly impact the Company due to the full valuation allowance that is recorded against the Company’s deferred tax assets. Early adoption of ASU 2019-12 is permitted, including adoption in any interim period for public business entities for periods for which financial statements have not yet been issued. An entity that elects to early adopt the amendments in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity that elects early adoption must adopt all the amendments in the same period. The Company will adopt ASU 2019-12 in 2021.

Restricted Cash (Tables)

3 Months Ended

Mar. 31, 2020

Restricted Cash [Abstract]

Schedule of Cash, Cash Equivalents, and Restricted Cash

Cash, cash equivalents, and restricted cash balances were as follows:

	March 31,		December 31,
(in thousands)		2020		2019
Cash and cash equivalents	$	4,540	$	10,002
Letters of credit		131		131
Security for credit cards		50		50
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$	4,721	$	10,183

Inventories (Tables)

3 Months Ended

Mar. 31, 2020

Inventory Disclosure [Abstract]

Schedule of inventories

Inventories consist of the following:

	March 31,		December 31,
(in thousands)	2020		2019
Raw materials	$	448	$	375
Work-in-process		342		279
Total inventories	$	790	$	654

Prepaid Expenses and Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2020

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

	March 31,		December 31,
(in thousands)	2020		2019
Clinical trial expenses	$	1,497	$	725
Insurance premiums		423		589
Professional Service Fees		518		—
Other¹		204		445
Total prepaid expenses and other current assets	$	2,642	$	1,759

Property, Plant, and Equipment (Tables)

3 Months Ended

Mar. 31, 2020

Property Plant And Equipment [Abstract]

Components of property, plant and equipment

Property, plant, and equipment consist of the following:

	March 31,			December 31,			Estimated
(in thousands)	2020			2019			Useful Life
Buildings and land	$	634		$	589		30 years - Buildings
Enterprise hardware and software		1,763			1,739		3 years
Leaseholds		1,787			1,695		Lesser of lease term or estimated useful life
Equipment		1,032			1,025		7 years
Furniture		202			198		5 years
Property, plant and equipment, gross		5,418			5,246
Accumulated depreciation		(4,551	)		(4,511	)
Property, plant and equipment, net	$	867		$	735

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2020

Payables And Accruals [Abstract]

Schedule of accrued expenses

Accrued expenses consist of the following:

	March 31,		December 31,
(in thousands)	2020		2019
Clinical Expenses	$	2,580	$	2,497
Compensation, excluding taxes		3,933		3,525
Professional fees		361		263
Other¹		550		662
Total accrued expenses	$	7,424	$	6,947

¹Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at March 31, 2020 and December 31, 2019.

Leases (Tables)

3 Months Ended

Mar. 31, 2020

Leases [Abstract]

Summary of Operating and Financing Leases

The following table summarizes the Company’s operating and financing leases as of and for the three months ended March 31, 2020:

(in thousands)	US			Ireland			Total
Lease Cost
Operating lease cost	$	118		$	52		$	170
Financing lease cost	12				—			12
Sublease income		—			(43	)		(43	)
Total	$	130		$	9		$	139

Other information
Operating cash flows out from operating leases		(118	)		(52	)		(170	)
Operating cash flows in from operating leases		-			43			43
Operating cash flows out from financing leases		(11	)		—			(11	)
Right-of-use assets exchanged for new operating lease liabilities		—			—			—
Weighted average remaining lease term		0.9			1.3
Weighted average discount rate - operating leases		8	%		8	%

Schedule of Maturity of Operating Leases Excluding Short-Term Leases

Maturities of the Company’s operating leases, excluding short-term leases, are as follows:

(in thousands)	US			Ireland			Total
Year ended December 31, 2020	$	369		$	154		$	523
Year ended December 31, 2021		78			120			198
Total		447			274			721
Less present value discount		(17	)		(15	)		(32	)
Operating lease liabilities included in the condensed consolidated balance sheet at March 31, 2020	$	430		$	259		$	689

Outstanding Debt (Tables)

3 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

Summary of Various Notes Issued

The following tables provide a summary of the various notes outstanding at March 31, 2020:

Conversion

price

Current interest

rate

Principal

Long term convertible notes payable

8.0% July 2019 Notes

1,500

2,000,000

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2020

Stockholders Equity Note [Abstract]

Summary of Stock Option Activity

The following is a summary of stock option activity under the Plan for the three months ended March 31, 2020:

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding at December 31, 2019		1,640	$	196.70	9.1	$	—
Granted		—
Exercised		—
Cancelled/Forfeited		—
Outstanding at March 31, 2020		1,640	$	196.70	8.9	$	—
Exercisable at March 31, 2020		1,640	$	196.70	8.9	$	—

Summary of Recognized Share-based Compensation Cost

	Three months ended March 31,
(in thousands)	2020		2019
Selling, general and administrative	$	49	$	43
Research and development		5		11
Total	$	54	$	54

Summary of Warrant Activity

The following is a summary of warrant activity for the three months ended March 31, 2020:

	Warrants			Exercise Price per Share	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)
Outstanding at December 31, 2019		1,826,608		$7.00 - $23.04	$	23.04		5.0
Issued		—
Exercised		—
Expired		(9	)
Outstanding at March 31, 2020		1,826,599		$7.00 - $23.04	$	23.04		4.7

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair value measurements using significant unobservable inputs

The table below presents the activity within Level 3 of the fair value hierarchy for the three months ended March 31, 2020

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

(in thousands)	Warrant Liability
Balance at December 31, 2019	$	3,368
Total change in the liability included in earnings		2,832
Fair value of warrants reclassified from liability to equity		(6,200	)
Balance at March 31, 2020	$	—

Schedule of fair value of the outstanding warrants

	February 19,	December 31,
	2020	2019
Expected life (in years)	4.3		4.6
Expected volatility	208.2%	207.5%
Risk-free interest rates	1.4%	1.7%

Assets and liabilities measured at fair value on a recurring basis

	Assets and Liabilities Measured at Fair Value on a Recurring Basis
(in thousands)	Level 1				Level 2				Level 3				Total
	March 31, 2020		December 31, 2019		March 31, 2020		December 31, 2019		March 31, 2020		December 31, 2019		March 31, 2020		December 31, 2019
Liabilities
Derivative instrument liabilities	$	—	$	—	$	—	$	—	$	—	$	3,368	$	—	$	3,368

Net Loss per Common Share (Tables)

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Anti-dilutive securities excluded from the computation of earnings per share

The following potentially dilutive securities were excluded from the computation of earnings per share as of March 31, 2020 and 2019 because their effects would be anti-dilutive:

	March 31,
	2020		2019
Stock options		1,640		1,166,667
Common stock warrants - equity		1,826,599		4,202,909
Common stock warrants - liabilities		—		189,029
Common stock reserved for conversion of preferred shares		1,799,093		—
Assumed conversion of convertible notes		63,493		268,558
Total		3,690,825		5,827,163

General - Additional Information (Details) $ in Millions	May 05, 2020 USD ($)
Common Stock [Member] \| Subsequent Event [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Gross proceeds from public offering	$ 22.0

Restricted Cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Restricted Cash [Abstract]
Cash and cash equivalents	$ 4,540	$ 10,002
Letters of credit	131	131
Security for credit cards	50	50
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$ 4,721	$ 10,183	$ 1,326	$ 3,578

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 448	$ 375
Work-in-process	342	279
Total inventories	$ 790	$ 654

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Prepaid Expense And Other Assets Current [Abstract]
Clinical trial expenses	$ 1,497	$ 725
Insurance premiums	423	589
Professional Service Fees	518
Other	204	445
Total prepaid expenses and other current assets	$ 2,642	$ 1,759

Prepaid Expenses and Other Current Assets - Additional Information (Details)	Mar. 31, 2020	Dec. 31, 2019
Prepaid Expense And Other Assets Current [Abstract]
Maximum percentage of prepaid expenses and other current assets (in hundredths)	5.00%	5.00%

Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 5,418	$ 5,246
Accumulated depreciation	(4,551)	(4,511)
Property, plant and equipment, net	867	735
Buildings and Land [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	634	589
Enterprise Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,763	1,739
Property, plant and equipment, estimated useful life	3 years
Leaseholds [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,787	1,695
Property, plant and equipment, estimated useful life	Lesser of lease term or estimated useful life
Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,032	1,025
Property, plant and equipment, estimated useful life	7 years
Furniture [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 202	$ 198
Property, plant and equipment, estimated useful life	5 years
Buildings [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, estimated useful life	30 years

Property, Plant, and Equipment - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Property Plant And Equipment [Abstract]
Depreciation expense	$ 0.1	$ 0.1

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Clinical Expenses	$ 2,580	$ 2,497
Compensation, excluding taxes	3,933	3,525
Professional fees	361	263
Other	550	662
Total accrued expenses	$ 7,424	$ 6,947

Accrued Expenses - Schedule of Accrued Expenses (Parenthetical) (Details)	Mar. 31, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Maximum percentage of current liabilities accrued (in hundredths)	5.00%	5.00%

Leases - Additional Information (Details)	Mar. 31, 2020
Leases [Abstract]
Lease term	12 months

Leases - Summary of Operating and Financing Leases (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($)
Lease Cost
Operating lease cost	$ 170
Financing lease cost	12
Sublease income	(43)
Total	139
Other information
Operating cash flows out from operating leases	(170)
Operating cash flows in from operating leases	43
Operating cash flows out from financing leases	(11)
U.S. [Member]
Lease Cost
Operating lease cost	118
Financing lease cost	12
Total	130
Other information
Operating cash flows out from operating leases	(118)
Operating cash flows out from financing leases	$ (11)
Weighted average remaining lease term	10 months 24 days
Weighted average discount rate - operating leases	8.00%
Ireland [Member]
Lease Cost
Operating lease cost	$ 52
Sublease income	(43)
Total	9
Other information
Operating cash flows out from operating leases	(52)
Operating cash flows in from operating leases	$ 43
Weighted average remaining lease term	1 year 3 months 18 days
Weighted average discount rate - operating leases	8.00%

Leases - Schedule of Maturity of Operating Leases Excluding Short-Term Leases (Details) $ in Thousands	Mar. 31, 2020 USD ($)
Lessee Lease Description [Line Items]
Year ended December 31, 2020	$ 523
Year ended December 31, 2021	198
Total	721
Less present value discount	(32)
Operating lease liabilities included in the condensed consolidated balance sheet at March 31, 2020	689
U.S. [Member]
Lessee Lease Description [Line Items]
Year ended December 31, 2020	369
Year ended December 31, 2021	78
Total	447
Less present value discount	(17)
Operating lease liabilities included in the condensed consolidated balance sheet at March 31, 2020	430
Ireland [Member]
Lessee Lease Description [Line Items]
Year ended December 31, 2020	154
Year ended December 31, 2021	120
Total	274
Less present value discount	(15)
Operating lease liabilities included in the condensed consolidated balance sheet at March 31, 2020	$ 259

Outstanding Debt - Additional Information (Details) $ / shares in Units, $ in Millions	Jun. 06, 2019 USD ($) $ / shares shares
Series E Preferred Stock and Related Warrants [Member]
Debt Instrument [Line Items]
Debt instrument, warrants price per unit \| $ / shares	$ 1,500
Senior Secured Promissory Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount \| $	$ 2.0
Interest rate	8.00%
Series D Warrants [Member]
Debt Instrument [Line Items]
Number of common shares issuable on cancellation of warrants	5,605
Pre-Funded Series D Warrants [Member]
Debt Instrument [Line Items]
Number of common shares issuable on cancellation of warrants	100,000

Outstanding Debt - Summary of Various Notes Issued (Details) - Long Term Convertible Notes Payable [Member] - 8.0% July 2019 Notes [Member]	Mar. 31, 2020 USD ($) $ / shares
Debt Instrument [Line Items]
Interest rate	8.00%
Conversion price \| $ / shares	$ 1,500
Principal \| $	$ 2,000,000

Stockholders' Equity - Preferred Stock Issuances - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	May 01, 2020	Jul. 11, 2019	May 05, 2020	Mar. 31, 2020	Dec. 31, 2019	Aug. 19, 2019	Jun. 06, 2019
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share)				$ 0.01	$ 0.01
Preferred stock, shares outstanding (in shares)				41,447	41,517
Number of warrants outstanding (in shares)				1,826,599	1,826,608
2019 Warrants [Member]
Stockholders Equity Note [Line Items]
Warrant exercise price				$ 23.04
Number of warrants outstanding (in shares)				1,800,000
Subsequent Event [Member] \| 2019 Warrants [Member]
Stockholders Equity Note [Line Items]
Offering price	$ 22.0
Warrant exercise price	$ 10.00		$ 10.00
Series E Convertible Preferred Stock [Member] \| July 2019 Private Placement [Member] \| Securities Purchase Agreement [Member]
Stockholders Equity Note [Line Items]
Number of shares issued		20,000
Preferred stock, par value (in dollars per share)		$ 0.01
Shares issued, price per share		$ 1,000
Series E Preferred Stock and Related Warrants [Member]
Stockholders Equity Note [Line Items]
Conversion price							$ 1,500
Series E Preferred Stock and Related Warrants [Member] \| July 2019 Private Placement [Member]
Stockholders Equity Note [Line Items]
Debt and warrants exchanged for preferred stock		$ 11.8
Number of preferred stock and warrants issued upon conversion		11,500
Value of accounts payable exchanged		$ 0.1
Number of shares issued upon exchange of accounts payable		149
Number of shares issued upon exchange of investor waiver rights		923
Series E-1 Convertible Preferred Stock [Member] \| August 2019 Private Placement [Member] \| Securities Purchase Agreement [Member]
Stockholders Equity Note [Line Items]
Number of shares issued						9,510
Preferred stock, par value (in dollars per share)						$ 0.01
Shares issued, price per share						$ 1,000
Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Conversion price				$ 23.04
Preferred Stock [Member] \| Subsequent Event [Member]
Stockholders Equity Note [Line Items]
Conversion price	$ 10.00
Offering price	$ 22.0

Stockholders' Equity - Common Stock Issuances - Additional Information (Details) - shares	Mar. 31, 2020	Dec. 31, 2019
Stockholders Equity Note [Line Items]
Common stock, shares issued (in shares)	72,773	67,091
Series E and E1 Convertible Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Common stock, shares issued (in shares)	2,915

Stockholders' Equity - Share-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense related to non-vested share-based compensation awards	$ 0
Share-based compensation (Income) expense	$ 54,000	$ 54,000
Compensation expense for issuance of restricted stock (in shares)	2,717
2019 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for grant	502
2019 Equity Incentive Plan [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance	2,142
2019 Equity Incentive Plan [Member] \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options, exercise price of common stock granted as percentage of fair value on the date of grant	100.00%

Stockholders' Equity - Summary of Stock Option Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Stockholders Equity Note [Abstract]
Number of Shares, Outstanding	1,640
Number of Shares, Outstanding	1,640	1,640
Number of Shares, Exercisable	1,640
Weighted Average Exercise Price, Outstanding	$ 196.70
Weighted Average Exercise Price, Outstanding	196.70	$ 196.70
Weighted Average Exercise Price, Exercisable	$ 196.70
Weighted Average Remaining Contractual Term (Years), Outstanding	8 years 10 months 24 days	9 years 1 month 6 days
Weighted Average Remaining Contractual Term (Years), Exercisable	8 years 10 months 24 days

Stockholders' Equity - Summary of Recognized Share-based Compensation Cost (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation (Income) expense	$ 54,000	$ 54,000
Selling, General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation (Income) expense	49,000	43,000
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation (Income) expense	$ 5,000	$ 11,000

Stockholders' Equity - Summary of Warrant Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Warrants outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	1,826,608
Warrants expired (in shares)	(9)
Outstanding, end of period (in shares)	1,826,599	1,826,608
Warrants, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 23.04
Outstanding, end of period (in dollars per share)	$ 23.04	$ 23.04
Weighted average remaining life	4 years 8 months 12 days	5 years
Minimum [Member]
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, (in dollars per share)	$ 7.00	$ 7.00
Maximum [Member]
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, (in dollars per share)	$ 23.04	$ 23.04

Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($)
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward]
Beginning balance	$ 3,368
Total change in the liability included in earnings	2,832
Fair value of warrants reclassified from liability to equity	$ (6,200)

Fair Value Measurements - Schedule of Fair Value of Outstanding Warrants (Details)	Feb. 19, 2020	Dec. 31, 2019
Contractual Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants expiration period	4 years 3 months 18 days	4 years 7 months 6 days
Expected Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants measurement input	2.082	2.075
Risk-free Interest Rates [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants measurement input	0.014	0.017

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Derivative Instruments Liabilities [Member] - Recurring [Member] $ in Thousands	Dec. 31, 2019 USD ($)
Liabilities [Abstract]
Total Liabilities	$ 3,368
Level 3 [Member]
Liabilities [Abstract]
Total Liabilities	$ 3,368

Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	3,690,825	5,827,163
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,640	1,166,667
Common Stock Warrants - Equity [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,826,599	4,202,909
Common Stock Warrants - Liabilities [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)		189,029
Common Stock Reserved For Conversion of Preferred Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,799,093
Assumed Conversion of Convertible Notes [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	63,493	268,558

Subsequent Events - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions			1 Months Ended	3 Months Ended
	May 05, 2020	May 01, 2020	May 14, 2020	Mar. 31, 2020	Dec. 31, 2019
Subsequent Event [Member] \| Series E and E1 Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion price	$ 10.00
Maximum [Member]
Subsequent Event [Line Items]
Warrant exercise price				$ 23.04	$ 23.04
Maximum [Member] \| Series F warrants [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Warrants issued to purchase of common stock	2,200,000
Minimum [Member]
Subsequent Event [Line Items]
Warrant exercise price				$ 7.00	$ 7.00
Common Stock [Member]
Subsequent Event [Line Items]
Convertible preferred stock, shares upon conversion				2,915
Common Stock [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Gross proceeds from public offering	$ 22.0
Common Stock [Member] \| Subsequent Event [Member] \| Series E and E1 Preferred Stock [Member]
Subsequent Event [Line Items]
Convertible preferred stock, shares upon conversion			800,000
Common Stock [Member] \| IPO \| Subsequent Event [Member]
Subsequent Event [Line Items]
Shares issued in public offering	2,200,000
2019 Warrants [Member]
Subsequent Event [Line Items]
Warrant exercise price				$ 23.04
2019 Warrants [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Gross proceeds from public offering		$ 22.0
Warrant exercise price	$ 10.00	$ 10.00